Gian Carlo Mattiucci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/717698/publications.pdf

Version: 2024-02-01

59 papers

1,230 citations

331259 21 h-index 395343 33 g-index

60 all docs 60 docs citations

60 times ranked

 $\begin{array}{c} 2031 \\ \text{citing authors} \end{array}$

#	Article	IF	CITATIONS
1	Survival after radiotherapy in gastric cancer: Systematic review and meta-analysis. Radiotherapy and Oncology, 2009, 92, 176-183.	0.3	84
2	Magnetic Resonance, Vendor-independent, Intensity Histogram Analysis Predicting Pathologic Complete Response After Radiochemotherapy of Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 765-774.	0.4	81
3	Artificial Intelligence in magnetic Resonance guided Radiotherapy: Medical and physical considerations on state of art and future perspectives. Physica Medica, 2021, 85, 175-191.	0.4	60
4	Chemoradiation and brachytherapy in biliary tract carcinoma: Long-term results. International Journal of Radiation Oncology Biology Physics, 2006, 64, 483-488.	0.4	55
5	Multi-institutional Pooled Analysis on Adjuvant Chemoradiation in Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 911-917.	0.4	55
6	Automatic delineation for replanning in nasopharynx radiotherapy: What is the agreement among experts to be considered as benchmark?. Acta Oncol \tilde{A}^3 gica, 2013, 52, 1417-1422.	0.8	49
7	Inter-observer variability of clinical target volume delineation in radiotherapy treatment of pancreatic cancer: a multi-institutional contouring experience. Radiation Oncology, 2014, 9, 198.	1.2	48
8	Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies. Medical Oncology, 2012, 29, 3478-3483.	1.2	44
9	Intensity-modulated Radiotherapy With Simultaneous Integrated Boost to Dominant Intraprostatic Lesion. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 158-162.	0.6	43
10	Clinical validation of atlas-based auto-segmentation of pelvic volumes and normal tissue in rectal tumors using auto-segmentation computed system. Acta Oncol \tilde{A}^3 gica, 2013, 52, 1676-1681.	0.8	39
11	Effect of Whole Pelvic Radiotherapy for Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy and Long-Term Androgen Deprivation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e721-e726.	0.4	37
12	The Prognostic Effect of Clinical Staging in Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2005, 12, 145-151.	0.7	36
13	Delta Radiomics Analysis for Local Control Prediction in Pancreatic Cancer Patients Treated Using Magnetic Resonance Guided Radiotherapy. Diagnostics, 2021, 11, 72.	1.3	31
14	Perioperative HDR Brachytherapy for Reirradiation in Head and Neck Recurrences: Single-institution Experience and Systematic Review. Tumori, 2017, 103, 516-524.	0.6	28
15	5-fluorouracil–based chemoradiation in unresectable pancreatic carcinoma: phase I-II dose-escalation study. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1454-1460.	0.4	27
16	Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers, 2020, 12, 1729.	1.7	26
17	Integration between <i>in vivo</i> dosimetry and image guided radiotherapy for lung tumors. Medical Physics, 2009, 36, 2206-2214.	1.6	24
18	Quality of Life and Toxicity of Stereotactic Radiotherapy in Pancreatic Tumors: A Case Series. Cancer Investigation, 2012, 30, 149-155.	0.6	23

#	Article	IF	CITATIONS
19	Low-Dose Hyperradiosensitivity: Is There a Place for Future Investigation in Clinical Settings?. International Journal of Radiation Oncology Biology Physics, 2010, 76, 535-539.	0.4	22
20	A Phase I study of high-dose-rate intraluminal brachytherapy as palliative treatment in extrahepatic biliary tract cancer. Brachytherapy, 2015, 14, 401-404.	0.2	22
21	Endoscopy-guided brachytherapy for sinonasal and nasopharyngeal recurrences. Brachytherapy, 2015, 14, 419-425.	0.2	22
22	Functional results of exclusive interventional radiotherapy (brachytherapy) in the treatment of nasal vestibule carcinomas. Brachytherapy, 2021, 20, 178-184.	0.2	22
23	Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a phase II trial. Anticancer Research, 2013, 33, 2785-9.	0.5	21
24	Radiochemotherapy with Gemcitabine in Unresectable Extrahepatic Cholangiocarcinoma: Long-term Results of a Phase II Study. Anticancer Research, 2016, 36, 737-40.	0.5	21
25	Chemoradiation and brachytherapy in extrahepatic bile duct carcinoma. Critical Reviews in Oncology/Hematology, 2014, 90, 58-67.	2.0	20
26	Early Proctoscopy is a Surrogate Endpoint of Late Rectal Toxicity in Prostate Cancer Treated With Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, e191-e195.	0.4	19
27	MITHRA – multiparametric MR/CT image adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a feasibility study. Journal of Contemporary Brachytherapy, 2015, 5, 336-345.	0.4	19
28	Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach. Radiation Oncology, 2014, 9, 45.	1.2	18
29	Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Translational Oncology, 2019, 12, 1-7.	1.7	18
30	Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 87-92.	0.8	17
31	The impact of radiomics in diagnosis and staging of pancreatic cancer. Therapeutic Advances in Gastrointestinal Endoscopy, 2022, 15, 263177452210815.	1.2	17
32	Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter caseâ€control study (PAULAâ€1). Cancer Medicine, 2020, 9, 7879-7887.	1.3	16
33	EROS study: evaluation between high-dose-rate and low-dose-rate vaginal interventional radiotherapy (brachytherapy) in terms of overall survival and rate of stenosis. Journal of Contemporary Brachytherapy, 2018, 10, 315-320.	0.4	13
34	Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: a multi-institutional contouring study on behalf of the AIRO group for gastrointestinal cancers. Acta Oncológica, 2019, 58, 439-447.	0.8	13
35	An application of visible human database in radiotherapy: tutorial for image guided external radiotherapy (TIGER). Radiotherapy and Oncology, 2004, 70, 165-169.	0.3	12
36	Long-term Analysis of Gemcitabine-based Chemoradiation after Surgical Resection for Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2013, 20, 423-429.	0.7	12

#	Article	IF	CITATIONS
37	Postoperative Intensity Modulated Radiation Therapy in High Risk Prostate Cancer: A Dosimetric Comparison. Medical Dosimetry, 2011, 36, 231-239.	0.4	11
38	Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. BMC Cancer, 2019, 19, 569.	1.1	11
39	Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multiarm Phase I trial. British Journal of Radiology, 2019, 92, 20180422.	1.0	10
40	Adjuvant radiotherapy with brachytherapy boost in soft tissue sarcomas. Journal of Contemporary Brachytherapy, 2017, 3, 256-262.	0.4	9
41	Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis. Journal of Contemporary Brachytherapy, 2019, 11, 21-27.	0.4	9
42	Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study. Future Oncology, 2016, 12, 779-787.	1.1	7
43	Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation. Cancers, 2022, 14, 431.	1.7	7
44	Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study. Acta Oncol \tilde{A}^3 gica, 2010, 49, 418-422.	0.8	6
45	Can automation in radiotherapy reduce costs?. Acta Oncológica, 2015, 54, 1282-1288.	0.8	6
46	Reducing Heart dose during Left Breast Cancer Radiotherapy: Comparison among 3 Radiation Techniques. Tumori, 2016, 102, 184-189.	0.6	6
47	Cost- and time-sparing simplified conformal therapy for prostate cancer: is it feasible?. International Journal of Radiation Oncology Biology Physics, 1998, 42, 65-71.	0.4	4
48	Development of a Modelling to Correlate Site and Diameter of Brain Metastases with Hippocampal Sparing Using Volumetric Modulated Arc Therapy. BioMed Research International, 2013, 2013, 1-6.	0.9	4
49	Radiation therapy for prostate cancer: What's the best in 2021. Urologia, 2022, 89, 5-15.	0.3	4
50	RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer. In Vivo, 2018, 31, 833-840.	0.6	4
51	Radioprotective effect of calcium channel blockers against late rectal bleeding in prostate cancer. Radiologia Medica, 2014, 119, 343-7.	4.7	3
52	Beyond geometrical overlap: a Dosimetrical Evaluation of automated volumes Adaptation (DEA) in head and neck replanning. Technical Innovations and Patient Support in Radiation Oncology, 2017, 3-4, 1-6.	0.6	3
53	Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients. Journal of Cancer Research and Clinical Oncology, 2021, 147, 661-667.	1.2	3
54	Recurrence in region of spared parotid gland in patient receiving definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A case report. Acta Oncológica, 2012, 51, 1095-1099.	0.8	2

#	Article	IF	CITATIONS
55	Intensified Adjuvant Treatment of Prostate Carcinoma: Feasibility Analysis of a Phase I/II Trial. BioMed Research International, 2014, 2014, 1-8.	0.9	2
56	Adjuvant Chemoradiotherapy in Gastric Cancer: A Pooled Analysis of the AIRO Gastrointestinal Group Experience. Tumori, 2015, 101, 91-97.	0.6	2
57	Patterns of radiotherapy practice for pancreatic cancer: Results of the Gastrointestinal Radiation Oncology Study Group multi-institutional survey. Oncology Reports, 2015, 34, 382-390.	1.2	1
58	Radiotherapy in cT3 Prostatic Carcinoma: Retrospective Comparison between Neoadjuvant and Adjuvant Hormonotherapy. Urologia Internationalis, 2004, 72, 21-27.	0.6	0
59	Hypofractionated stereotactic radiotherapy for oligometastatic patients: developing of a response predictive model. Medical Oncology, 2018, 35, 146.	1.2	0